Clinical trials: active, sponsored by UNICANCER
Breast Cancer Metastatic, Breast Cancer Stage IV
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the…
- Trial name
- SAFIR3LibHERty (NCT06680596)
- Testing
- trastuzumab derxutecan
- Where
- 40 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER
Breast Cancer (Early Breast Cancer)
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse.
- Trial name
- NoELA (NCT07661927)
- Testing
- Removing Endocrine Therapy
- Where
- 41 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER
Advanced / Metastatic Solid Tumors, Advanced Malignancy
Immunotherapy Master Trial for Advanced Cancers
Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors.
- Trial name
- METAREM (NCT07431073)
- Testing
- METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each
- Where
- France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Leiomyosarcoma Uterus
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Addition of postoperative chemotherapy to prevent or delay recurrence in patients newly diagnosed with localized uterine leiomyosarcoma and who have undergone complete tumor surgery.
- Trial name
- L-UteCIN (NCT06524583)
- Testing
- Doxorubicin, Trabectedin
- Where
- 25 sites in France
- Volunteers
- 198 people
- Sponsor
- UNICANCER
Non Small Cell Lung Cancer (Squamous or Non Squamous)
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
Anti-PD-1 monotherapy has demonstrated significant clinical efficacy in advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score [TPS] >50%), outperforming platinum-based…
- Trial name
- META-1 (NCT07360743)
- Testing
- Pembrolizumab, Cemiplimab
- Where
- 4 sites in France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Biliary Tract Cancer
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
The object of this trial is to test whether ivonescimab is superior to standard chemotherapy (FOLFOX regimen) for the treatment of patients with advanced biliary tract cancer after failure of a first line of chemotherapy.
- Trial name
- SEVILLA (NCT06529718)
- Testing
- Ivonescimab, FOLFOX regimen
- Where
- 42 sites in France, United Kingdom
- Volunteers
- 72 people
- Sponsor
- UNICANCER
Biliary Tract Cancer (BTC)
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
The objective of SAFIR-IMPACT BTC is to see whether, combining or replacing the standard adjuvant chemotherapy with a targeted therapy matched to the person's cancer, is better than the standard treatment alone in delaying or…
- Trial name
- SAFIR-IMPACT (NCT07745296)
- Testing
- Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine
- Volunteers
- 990 people
- Sponsor
- UNICANCER
Triple-Negative Breast Neoplasm
Tracking Triple-negative Breast Cancer Evolution Through Therapy
A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative…
- Trial name
- TRACERX-TNBC (NCT03077776)
- Testing
- Biopsy, Biopsy (optional), Biopsy (metastatic)
- Where
- 10 sites in France
- Volunteers
- 149 people
- Sponsor
- UNICANCER
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Home Based Standardised Adapted Physical Activity Programme, Patients Taking Oral Targeted Therapy for Metastatic Cancer
QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program
This phase II-III study will be randomized (2:1) patients starting first-line oral targeted therapies (OTT) for metastatic cancer between an individualized supervised physical exercise programs (SPEP) by a personal coach, and…
- Trial name
- QUALIOR (NCT03169075)
- Testing
- Supervised physical exercise programs, Adapted physical activity
- Where
- 15 sites in France
- Volunteers
- 190 people
- Sponsor
- UNICANCER
Lynch Syndrome
Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome
Lynch syndrome is an inherited genetic predisposition that increases the risk of developing several types of cancer, particularly colon and rectal cancers (colorectal cancer), as well as cancer of the uterine lining (endometrial…
- Trial name
- PREDI-LYNCH (NCT07360834)
- Testing
- INVITRO DIAGNOSTIC TESTS AND COLONOSCOPY
- Where
- 9 sites in Croatia, Czechia and 7 more
- Volunteers
- 2,000 people
- Sponsor
- UNICANCER
Metastatic (Stage IV) Melanoma
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body).
- Trial name
- EPIBREAST (NCT07340619)
- Testing
- prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant
- Where
- 8 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Triple Negative Breast Neoplasms, Neoplasm Metastasis
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
This is a phase II, multicentre, open-label, randomised controlled trial (patients are randomly assigned to one treatment arm or the other) evaluating two treatment strategies (sacituzumab govitecan and trastuzumab deruxtecan in…
- Conditions
- Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer
- Trial name
- ALTER (NCT07151586)
- Testing
- Sacituzumab Govitecan / Trastuzumab Deruxtecan
- Where
- 2 sites in France
- Volunteers
- 260 people
- Sponsor
- UNICANCER
Early Breast Cancer, Premenopausal Breast Cancer
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Rationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug…
- Conditions
- Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
- Trial name
- OPTIMA-YOUNG (NCT07106632)
- Testing
- test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy
- Where
- 105 sites in Belgium, France and 5 more
- Volunteers
- 3,380 people
- Sponsor
- UNICANCER
Prostate Cancer
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00967863
- Testing
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Squamous Cell Carcinoma of Head and Neck
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Study to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
- Trial name
- PembroMetaRT (NCT04747054)
- Testing
- Pembrolizumab, Loco-regional radiotherapy, Chemotherapy
- Where
- 26 sites in France
- Volunteers
- 102 people
- Sponsor
- UNICANCER
Primary Non-metastatic Breast Cancer, Who Remain Disease-free
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
A significant number of patients relapse and eventually die, particularly if they were initially diagnosed with large nodes involvement and/or T3/4 diseases.
- Trial name
- NCT01805271
- Testing
- Everolimus
- Where
- 2 sites in France
- Volunteers
- 1,278 people
- Sponsor
- UNICANCER
Hereditary Breast and Ovarian Cancer, Mutation
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
TUMOSPEC is a national family study designed to measure the relative and absolute risk of cancer for carriers of deleterious mutations to these "new" breast cancer (BC) susceptibility genes.
- Trial name
- TUMOSPEC (NCT03246841)
- Testing
- Genetic testing
- Where
- 2 sites in France
- Volunteers
- 7,274 people, healthy volunteers welcome
- Sponsor
- UNICANCER
Locally Advanced or Metastatic Breast Cancer
Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.
OASIS-ImmunoPET is a monocentric pilot study evaluating antibody imaging to predict response to antibody-drug conjugate (ADC), an innovative cancer targeted therapy, and potentially replace tumor biopsy.
- Trial name
- OASISImmunoPET (NCT07294430)
- Testing
- Immuno-PET
- Volunteers
- 30 people
- Sponsor
- UNICANCER
High Risk Prostate Carcinoma, Prostate Cancer
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
PEACE 7 is an international, multicenter, randomized, open-label phase III study that aims at evaluating the efficacy and safety of darolutamide and of stereotactic dose escalated prostate radiotherapy in patients with localised…
- Trial name
- PEACE 7 (NCT06625970)
- Testing
- Darolutamide, Stereotactic Body RadioTherapy (SBRT), ADT (Standard of Care)
- Where
- 6 sites in France, Martinique
- Volunteers
- 700 people
- Sponsor
- UNICANCER